The latest price target for Telix Pharmaceuticals (NASDAQ:TLX) was reported by UBS on January 27, 2025. The analyst firm set a price target for $22.00 expecting TLX to rise to within 12 months (a possible 25.00% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Telix Pharmaceuticals (NASDAQ:TLX) was provided by UBS, and Telix Pharmaceuticals maintained their buy rating.

There is no last upgrade for Telix Pharmaceuticals

There is no last downgrade for Telix Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Telix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Telix Pharmaceuticals was filed on January 27, 2025 so you should expect the next rating to be made available sometime around January 27, 2026.

While ratings are subjective and will change, the latest Telix Pharmaceuticals (TLX) rating was a maintained with a price target of $21.00 to $22.00. The current price Telix Pharmaceuticals (TLX) is trading at is $17.60, which is out of the analyst’s predicted range.